Molecular, physiological and genetic “experiments of nature” have provided important clues to the pathophysiology underlying human obesity and have revealed molecular targets for the development of new medications to combat this disease. This session will include three presentations of the results of late-breaking phase 2 and 3 clinical studies of novel anti-obesity medications, along with a state-of-the art lecture describing several promising targets and medications in preclinical and early clinical development.


11:00am Anti-Obesity Pharmacotherapy – Opportunities, Challenges and Recent Progress
Mads Tang-Christensen
11:30am Bimagrumab, an Activin Receptor Antagonist, for Treatment of Obesity and Type 2 Diabetes
Laura A Coleman, PhD RD
11:45am Efficacy and Safety of the MC4R Agonist Setmelanotide in POMC Deficiency Obesity: A Phase 3 Trial
Peter Kuehnen
12:00pm Efficacy and Safety of the MC4R Agonist Setmelanotide in LEPR Deficiency Obesity: A Phase 3 Trial
Erica Van Den Akker, MD PhD
12:15pm Panel Discussion on Clinical Implications of Emerging Pharmacotherapeutic Agents for Obesity
Peter Kuehnen; Laura A Coleman, PhD RD; Erica Van Den Akker, MD PhD; Mads Tang-Christensen